Announcement of The Conolidated Financial Report for The 3rd Quarter of 2021
2021.11.4
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2021/11/04 | Time of announcement | 17:04:13 |
| Subject | Announcement of The Conolidated Financial Report for The 3rd Quarter of 2021 | ||||
| Date of events | 2021/11/04 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the financial reports submitted to the board of directors or approved by the board of directors:2021/11/04 2.Date of the financial reports approved by the audit committee:2021/11/04 3.Start and end dates of financial reports of the reporting period:2021/01/01~2021/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):3,067,163 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,927,589 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):763,881 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):661,816 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):483,695 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):488,378 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):1.96 11.Total assets end of the period (thousand NTD):9,734,616 12.Total liabilities end of the period (thousand NTD):4,276,432 13.Equity attributable to owners of parent end of the period (thousand NTD):4,844,127 14.Any other matters that need to be specified:None |
||||